MX2021016066A - Anticuerpos heterodimericos que se unen a cd38 y cd3. - Google Patents

Anticuerpos heterodimericos que se unen a cd38 y cd3.

Info

Publication number
MX2021016066A
MX2021016066A MX2021016066A MX2021016066A MX2021016066A MX 2021016066 A MX2021016066 A MX 2021016066A MX 2021016066 A MX2021016066 A MX 2021016066A MX 2021016066 A MX2021016066 A MX 2021016066A MX 2021016066 A MX2021016066 A MX 2021016066A
Authority
MX
Mexico
Prior art keywords
polypeptide
heterodimeric antibodies
bind
antibodies
heterodimeric
Prior art date
Application number
MX2021016066A
Other languages
English (en)
Inventor
Barbara A Swanson
Gunnar F Kaufmann
Susan M Richards
Yanliang Zhang
Xiao He
yun wei Lai
Lisa Diane Kerwin
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of MX2021016066A publication Critical patent/MX2021016066A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente divulgación proporciona anticuerpos heterodiméricos que se unen a dos antígenos blanco diferentes al mismo tiempo. En una modalidad, los anticuerpos heterodiméricos son anticuerpos biespecíficos. En una modalidad, los anticuerpos heterodiméricos comprenden tres polipéptidos que incluyen: un primer polipéptido que comprende un polipéptido de fusión scFv-Fc; un segundo polipéptido que comprende una cadena pesada de inmunoglobulina; y un tercer polipéptido que comprende una cadena ligera de inmunoglobulina. En una modalidad, el primer polipéptido incluye una o más mutaciones puntuales que confieren una mayor estabilidad térmica al primer polipéptido.
MX2021016066A 2019-07-01 2020-06-30 Anticuerpos heterodimericos que se unen a cd38 y cd3. MX2021016066A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962869343P 2019-07-01 2019-07-01
US201962890163P 2019-08-22 2019-08-22
US201962945350P 2019-12-09 2019-12-09
PCT/US2020/040360 WO2021003189A1 (en) 2019-07-01 2020-06-30 Heterodimeric antibodies that bind to cd38 and cd3

Publications (1)

Publication Number Publication Date
MX2021016066A true MX2021016066A (es) 2022-05-18

Family

ID=74100698

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021016066A MX2021016066A (es) 2019-07-01 2020-06-30 Anticuerpos heterodimericos que se unen a cd38 y cd3.

Country Status (10)

Country Link
US (1) US20220363758A1 (es)
EP (1) EP3993831A1 (es)
JP (1) JP2022538461A (es)
KR (1) KR20220030276A (es)
CN (1) CN114340668A (es)
AU (1) AU2020301003A1 (es)
CA (1) CA3144961A1 (es)
IL (1) IL289497A (es)
MX (1) MX2021016066A (es)
WO (1) WO2021003189A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024513238A (ja) * 2021-04-09 2024-03-22 ソレント・セラピューティクス・インコーポレイテッド 抗ｒｏｒ１／抗ｃｄ３二重特異性抗体を発現する腫瘍溶解性ウイルス
CA3226428A1 (en) * 2021-08-02 2023-02-09 Hangzhou Unogen Biotech, Ltd Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381803B1 (en) * 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
KR102391731B1 (ko) * 2013-01-14 2022-04-27 젠코어 인코포레이티드 신규한 이형이량체 단백질
TN2017000222A1 (en) * 2014-11-26 2018-10-19 Xencor Inc Heterodimeric antibodies that bind cd3 and cd38
US20180305465A1 (en) * 2015-11-25 2018-10-25 Amgen Inc. Heterodimeric antibodies that bind cd3 and cd38
CA3080109A1 (en) * 2017-11-03 2019-05-09 Sorrento Therapeutics, Inc. Cd38-directed chimeric antigen receptor constructs

Also Published As

Publication number Publication date
EP3993831A1 (en) 2022-05-11
IL289497A (en) 2022-02-01
CN114340668A (zh) 2022-04-12
JP2022538461A (ja) 2022-09-02
CA3144961A1 (en) 2021-01-07
US20220363758A1 (en) 2022-11-17
AU2020301003A1 (en) 2022-02-17
WO2021003189A1 (en) 2021-01-07
KR20220030276A (ko) 2022-03-10

Similar Documents

Publication Publication Date Title
PH12020550408A1 (en) Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
WO2018057735A8 (en) Antibodies for siglec-15 and methods of use thereof
MX2020003145A (es) Nuevos complejos de polipeptidos biespecificos.
PH12018500295A1 (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
CR20170383A (es) Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
CR20200171A (es) Contorsbodies 2 + 1 biespecíficos
ZA202100390B (en) Fusion constructs and methods of using thereof
MX2021001711A (es) Proteínas biespecíficas modificadas.
TN2019000275A1 (en) Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof
EA202191457A1 (ru) Анти-pd-l1/анти-4-1bb биспецифические антитела и их применения
WO2017152102A3 (en) Anti-trem1 antibodies and methods of use thereof
MX2022007636A (es) Anticuerpos biespecificos caninizados y pares de union biespecificos para el tratamiento contra dermatitis atopica.
AR105267A1 (es) Anticuerpos de unión a tau
WO2019195623A3 (en) Heterodimeric antibodies that bind fibroblast activation protein
IL285980A (en) Heterodimeric antibodies that bind enpp3 and cd3
MX2021016066A (es) Anticuerpos heterodimericos que se unen a cd38 y cd3.
MX2021005048A (es) Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
SG10201801219VA (en) Anti-HER2 Antibodies
WO2017124001A3 (en) T cell receptor-like antibodies specific for foxp3-derived peptides
EP4065164A4 (en) ANTIBODIES AGAINST CD3 AND BCMA AND BISPECIFIC BINDING PROTEINS PRODUCED THEREOF
CR20210628A (es) Fragmentos de unión al antígeno cd3 y composiciones que comprenden los mismos
EP4268848A3 (en) Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy
IL305736A (en) Heterodimeric antibodies that bind CD3 and CLDN6
MX2022003465A (es) Anticuerpo monoclonal contra proteína de activación de fibroblasto canino de reacción cruzada con proteína de activación de fibroblasto (fap) de ratón y humana.